CSIMarket


Terms Beginning with O
                       
                       
 Off-Label   Option   Osteonecrosis  
 On Balance Volume OBV   Option ARMs Mortgage Loans   OTC  
 Oncology   Ore   Ounce  
 Open Pit Mine   Ore Body   Out of The Money Option  
 Open-label Clinical Trial   Ore Reserves   Out-License  
 Operating Cost Per Available Seat Mile Cost Per ASM CASM   Origination Fees   Overburden Mining  
 Operating Income Growth Rates   Orphan Drug   Overhead Ratio  
 Operating Margin   OSB Oriented strand board   Oxide  
 Operating Profit Margin   OSHA Recordable Rate     
 Operating revenue yield per Available Seat Mile Average Yield per ASM   Osteoarthritis     
                 
                   
 
 
       
       
 

Off-Label

Health Care Term


Off-label refers to the use of a medication, medical device, or diagnostic test for a purpose that has not been approved by regulatory agencies such as the Food and Drug Administration (FDA). In other words, it is the use of a product for a condition or patient population that is not included on the product label.

Off-label use is common in the healthcare industry, particularly for medications. Physicians may prescribe a medication for a condition that is not listed on the official label, or they may adjust the dosage or route of administration. This practice is legal, and in some cases, it may be the only treatment option available for a particular patient.

However, off-label use comes with potential risks for patients. Since the product was not initially developed or tested for the particular condition, and the effects of off-label use may not be thoroughly studied or well understood, it may pose an increased risk of adverse effects or ineffective outcomes. Patients who receive off-label treatments should be carefully monitored and informed of the potential risks.

In some cases, pharmaceutical companies may also promote off-label use of their products, which is illegal. This practice may be motivated by financial gain rather than clinical evidence, and it poses risks to patients who may be prescribed treatments that are not supported by scientific evidence.

Overall, off-label use is a complex issue in the healthcare industry that requires balance between the need for innovative treatments and the safety of patients. Physicians and healthcare providers should weigh the potential risks and benefits of off-label treatments when deciding on treatment options for their patients.


   
     

Off-Label

Health Care Term


Off-label refers to the use of a medication, medical device, or diagnostic test for a purpose that has not been approved by regulatory agencies such as the Food and Drug Administration (FDA). In other words, it is the use of a product for a condition or patient population that is not included on the product label.

Off-label use is common in the healthcare industry, particularly for medications. Physicians may prescribe a medication for a condition that is not listed on the official label, or they may adjust the dosage or route of administration. This practice is legal, and in some cases, it may be the only treatment option available for a particular patient.

However, off-label use comes with potential risks for patients. Since the product was not initially developed or tested for the particular condition, and the effects of off-label use may not be thoroughly studied or well understood, it may pose an increased risk of adverse effects or ineffective outcomes. Patients who receive off-label treatments should be carefully monitored and informed of the potential risks.

In some cases, pharmaceutical companies may also promote off-label use of their products, which is illegal. This practice may be motivated by financial gain rather than clinical evidence, and it poses risks to patients who may be prescribed treatments that are not supported by scientific evidence.

Overall, off-label use is a complex issue in the healthcare industry that requires balance between the need for innovative treatments and the safety of patients. Physicians and healthcare providers should weigh the potential risks and benefits of off-label treatments when deciding on treatment options for their patients.


Related Health Care Terms
                     
                     
 Adenocarcinoma   Analogues   Arrhythmia  
 Adenosine   ANDA Abbreviated New Drug Application   Arteriosclerosis  
 Adult Stem Cell   Angina   Atherosclerosis  
 Adverse Event   Angiogenesis   Autologous  
 Agonist   Angioplasty   Balloon Angioplasty  
 AIDS   Antagonist   Bioavailability  
 Alkylation Agent   Anti Hypertensive   Biologic Products  
 Allogeneic   Antibody   Biomarker  
 Amino Acid   Antigen   Bradycardia  
 Analgesic   API   Cancer  
               
                  next arrow
 
   


Help

About us

Advertise